miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway

Tumor Biology

Volumn 35, Issue 2, 2014, Pages 1287-1295

  Cao, Weiguo ^a   Yang, Weiping ^a   Fan, Rong ^a   Li, Hao ^a   Jiang, Jinsong ^a   Geng, Mei ^a   Jin, Yening ^a   Wu, Yunlin ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis; Cisplatin; Gastric cancer; miR 34a; PI3K AKT survivin

Indexed keywords

CISPLATIN; MICRORNA 34A; PHOSPHATIDYLINOSITOL 3 KINASE; PROPIDIUM IODIDE; PROTEIN KINASE B; SURVIVIN; SYNEXIN; WORTMANNIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL DEATH; CELL VIABILITY; CONTROL GROUP; DOWN REGULATION; DRUG SENSITIVITY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MTT ASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STAINING; STOMACH CANCER; UPREGULATION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CISPLATIN; ELAFIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICRORNAS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84898893803     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1171-7     Document Type: Article

References (43)

1. Li XJ, Xie HL, Lei SJ, et al. Reduction of CAII expression in gastric cancer: correlation with invasion and metastasis. Chin J Cancer Res. 2012;24:196-200.
2. Shan F, Ji J. Updating advances and controversies on the multidisciplinary therapy of gastric cancer. Transl Gastrointest Cancer. 2012;1: 151-60.
3. Hu B, El Hajj N, Sittler S, et al. Gastric cancer: classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012;3:251-61.
4. Wu A, Ji J. The 7th National Gastric Cancer Academic Conference: focus on translational research in gastric cancer. Transl Gastrointest Cancer. 2012;1:277-83.
5. Leja M, Wex T, Malfertheiner P. Markers for gastric cancer premalignant lesions: where do we go? Dig Dis. 2012;30:268-76.
6. Sun Y, Tian MM, Zhou LX, et al. Value of c-Met for predicting progression of precancerous gastric lesions in rural Chinese population. Chin J Cancer Res. 2012;24:18-22.
7. Zhang CD, Zeng YJ, Li HW, et al. Neoadjuvant chemotherapy for nonmetastatic esophago-gastric adenocarcinomas: a systematic review and meta-analysis. Cancer Invest. 2013.
8. Correa P. Gastric cancer: overview. Gastroenterol Clin North Am. 2013;42(2):211-7.
9. Zhao X, Li X, Yuan H. microRNAs in gastric cancer invasion and metastasis. Front Biosci. 2013;18:803-10.
10. SanfordM. S-1 (teysuno((R))): a review of its use in advanced gastric cancer in non-Asian populations. Drugs. 2013;73(8):845-55.
11. Ema A, Yamashita K, Sakuramoto S, et al. Lymph node ratio is a critical prognostic predictor in gastric cancer treated with S-1 chemotherapy. Gastric Cancer. 2013.
12. Chen XL, Chen XZ, Yang C, et al. Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis. PLoS One. 2013;8(4):e60320.
13. Taketa T, Sudo K, Wadhawa R, et al. Adjuvant therapy in gastric cancer: what is the optimal approach? Curr Oncol Rep. 2013;15(2):146-51.
14. Shi WT, Wei L, Xiang J, et al. Chinese patients with gastric cancer need targeted adjuvant chemotherapy schemes. Asian Pac J Cancer Prev. 2012;13(10):5263-72.
15. Huang JY, Xu YY, Sun Z, et al. Comparison different methods of intraoperative and intraperitoneal chemotherapy for patients with gastric cancer: a meta-analysis. Asian Pac J Cancer Prev. 2012;13(9):4379-85.
16. Kong YW, Ferland-McCollough D, Jackson TJ, et al. microRNAs in cancer management. Lancet Oncol. 2012;13(6):e249-258.
17. Wiwanitkit S, Wiwanitkit V. MicroRNA from tuberculosis RNA: a bioinformatics study. J Thorac Dis. 2012;4(3):296-7.
18. Lee CH, Chiu YC, Wang LB, Kuo YL, Chuang EY, Lai LC, et al. Common applications of next-generation sequencing technologies in genomic research. Transl Cancer Res. 2013;2(1):33-45.
19. Zhou X, Yuan P, He Y. Role of microRNAs in peripheral artery disease (review). Mol Med Report. 2012;6(4):695-700.
20. McDaniel K, Correa R, Zhou T, et al. Functional role of microvesicles in gastrointestinal malignancies. Ann Transl Med. 2013;1:4.
21. Ui-Tei K, Nishi K, Takahashi T, et al. Thermodynamic control of small RNA-mediated gene silencing. Front Genet. 2012;3:101.
22. Yang JS, Maurin T, Lai EC. Functional parameters of Dicer-independent microRNA biogenesis. RNA. 2012;18(5):945-57.
23. Weiland M, Gao XH, Zhou L, et al. Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases. RNA Biol. 2012;9(6):850-9.
24. Du L, Pertsemlidis A. microRNA regulation of cell viability and drug sensitivity in lung cancer. Expert Opin Biol Ther. 2012;12(9):1221-39.
25. Yamamoto H, Adachi Y, Taniguchi H, et al. Interrelationship between microsatellite instability and microRNA in gastrointestinal cancer. World J Gastroenterol. 2012;18(22):2745-55.
26. Wong MY, Yu Y, Walsh WR, et al. microRNA-34 family and treatment of cancers with mutant or wild-type p53 (Review). Int J Oncol. 2011;38(5):1189-95.
27. O'Day E, Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res. 2010;12(2):201.
28. Cha YH, Kim NH, Park C, et al. MiRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling. Cell Cycle. 2012;11(7):1273-81.
29. Balca-Silva J, Neves SS, Goncalves AC, et al. Effect of miR-34b overexpression on the radiosensitivity of non-small cell lung cancer cell lines. Anticancer Res. 2012;32(5):1603-9.
30. Cao W, Fan R, Wang L, et al. Expression and regulatory function of miRNA-34a in targeting survivin in gastric cancer cells. Tumour Biol. 2013;34(2):963-71.
31. Franchina T, Amodeo V, Bronte G, et al. Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer. J Cell Physiol. 2013.
32. Li XJ, Ji MH, Zhong SL, et al. MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1. Arch Med Res. 2012;43(7):514-21.
33. Yao Y, Suo AL, Li ZF, et al. MicroRNA profiling of human gastric cancer. Mol Med Report. 2009;2(6):963-70.
34. Wong KY, Yu L, Chim CS. DNA methylation of tumor suppressor miRNA genes: a lesson from the miR-34 family. Epigenomics. 2011;3(1):83-92.
35. Kumar B, Yadav A, Lang J, et al. Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis. PLoS One. 2012;7(5):e37601.
36. Shen Z, Zhan G, Ye D, et al. MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin. Med Oncol. 2012;29(4):2473-80.
37. Jagadeesh D, Smith MR. Novel targeted therapies in peripheral T cell lymphoma. Discov Med. 2013;15(85):367-78.
38. Morotti M, Becker C, Menada MV, et al. Targeting tyrosine-kinase in ovarian cancer. Expert Opin Investig Drugs. 2013.
39. Lubin J, Markowska A, Knapp P. Factors affecting response of chemotherapy in women with ovarian cancer. Eur J Gynaecol Oncol. 2012;33(6):644-7.
40. Breier A, Gibalova L, Seres M, et al. New insight into P-glycoprotein as a drug target. Anticancer Agents Med Chem. 2013;13(1):159-70.
41. De Luca A, Maiello MR, D'Alessio A, et al. The RAS/RAF/MEK/ ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 2012;16 Suppl 2:S17-27.
42. Aksamitiene E, Kiyatkin A, Kholodenko BN. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem Soc Trans. 2012;40(1):139-46.
43. Du F, Wu X, Liu Y, et al. Acquisition of paclitaxel resistance via PI3K-dependent epithelial-mesenchymal transition in A2780 human ovarian cancer cells. Oncol Rep. 2013.